In a randomized trial, intravenous aspirin did not improve outcomes, and possibly increased intracranial hemorrhage risk, when given within 90 minutes after TPA.
Tissue plasminogen activator (TPA) is an imperfect therapy for acute ischemic stroke, because it often fails to recanalize blocked vessels or prevent reocclusion after initial recanalization. Observational data suggest that patients already on antiplatelet therapy may have more recanalization and better outcomes after TPA, but current guidelines recommend withholding aspirin for 24 hours after TPA administration.
To better assess the effect of aspirin therapy on thrombolysis results, investigators performed a multicenter, randomized, open-label trial of 300 mg of intravenous aspirin given within 90 minutes after intravenous TPA administration for acute ischemic stroke (“early aspirin”). Patients who had taken antiplatelet or anticoagulant dr…
Reviewing Author
DisclosuresSpeaker’s bureauGenentech
Grant / Research supportNational Institutes of Health/National Institute of Neurological Disorders and Stroke; Michael Goldberg Stroke Research Fund
Editorial boardsPLOS One; Scientific Reports
Leadership positions in professional societiesNeurocritical Care Society (Research Committee Member)
DisclosuresSpeaker’s bureauGenentech
Grant / Research supportNational Institutes of Health/National Institute of Neurological Disorders and Stroke; Michael Goldberg Stroke Research Fund
Editorial boardsPLOS One; Scientific Reports
Leadership positions in professional societiesNeurocritical Care Society (Research Committee Member)